Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

LivaNova PLC Ordinary Shares

LIVN

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Last trade $92.47
Day change +$0.03 (+0.03%)
Day range $91.77 – $95.33
Volume 218,451
Market cap $5.09B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.09B
Price / earnings
25.97×
Price / book
3.71×
Price / sales
3.38×
EV / sales
3.2×
EV / EBITDA
22.17×

Profitability

Earnings per share
$3.56
Return on assets
7.23%
Return on equity
14.29%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.22×
Current ratio
3.04×
Quick ratio
2.54×
Cash ratio
1.58×

Cash flow

Price / cash flow
21.41×
Price / free cash flow
39.47×
Free cash flow
$129.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LIVN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$393.15M$390.59M$362.26M$360.92M$357.75M$352.52M$316.86M$321.83M
Cost of revenue$128.1M$116.92M$118.51M$121.15M$112.9M$113.54M$100.6M$107.46M
Gross profit$265.05M$273.67M$243.75M$239.77M$244.86M$238.99M$216.25M$214.37M
Selling, general and administrative$154.93M$158.13M$143.57M$143.37M$138.52M$137.78M$129.15M$130.64M
Research and development$47.69M$53.66M$58.7M$52.12M$48.58M$47.19M$37.88M$43.31M
Total operating expenses$236.63M$224.19M$202.28M$197.2M$190.84M$184.81M$528.03M$177.35M
Operating income$28.43M$49.48M$41.47M$42.58M$54.01M$54.18M-$311.78M$37.02M
Interest expense-$7.95M-$7.18M-$8.29M-$10.86M-$10.86M-$14.93M-$15.29M-$15.77M
Income before taxes$46.77M$18.48M$27.49M$27.63M$33.91M$33.32M-$315.65M$56.48M
Income taxes$12.4M-$90.2M$4.34M-$3.28M$7.11M$6.15M$11.66M$589K
Net income$34.29M$108.57M$22.29M$30.91M$26.78M$27.16M-$327.32M$55.89M
Net income attributable to common shareholders$34.29M$108.57M$22.29M$30.91M$26.78M$27.16M-$327.32M$55.89M
EBITDA$43.91M$64.9M$54.33M$54.65M$66.26M$65.5M-$301.14M$47.69M
Basic earnings per share$0.62$1.98$0.41$0.57$0.49$0.50-$6.01$1.03
Diluted earnings per share$0.11$1.93$0.40$0.57$0.49$0.50-$6.01$1.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

Zacks Investment Research

LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates

LivaNova (LIVN) reported Q3 2026 earnings of $1.23 per share, beating consensus estimates of $1.03 and delivering a 19.42% surprise. Revenue reached $393.1 million, surpassing estimates by 3.43%. The company has outperformed market expectations for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries.

Zacks Investment Research

Waters (WAT) Beats Q3 Earnings and Revenue Estimates

Waters Corporation reported Q3 2026 earnings of $4.1 per share, beating consensus estimates of $3.99, with revenues of $1.77 billion exceeding expectations by 0.81%. The company has consistently beaten estimates over the last four quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Waters shares have gained 18.4% year-to-date versus the S&P 500's 10.2% gain.

Zacks Investment Research

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

ClearPoint Neuro reported a Q3 loss of $0.24 per share, beating expectations of $0.32 loss, but missed revenue estimates with $12.08 million versus consensus. The company has underperformed the S&P 500 by 41% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

GlobeNewswire Inc.

Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.